Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery: A Multicenter, Randomized, Parallel-Control, Non-Inferiority Trial
Zhongshan Ophthalmic Center, Sun Yat-sen University
204 participants
Jan 22, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if Anrikefon works as well as nalbuphine to control postoperative pain in adults undergoing ophthalmic surgery under general anesthesia. It will also learn about the safety and recovery outcomes of using Anrikefon. The main questions it aims to answer are: * Does Anrikefon provide pain relief that is not inferior to nalbuphine after ophthalmic surgery? * Does Anrikefon cause fewer central side effects, such as sedation or dizziness, compared with nalbuphine? * Does Anrikefon help patients recover and get discharged faster after day-surgery procedures? Researchers will compare Anrikefon to nalbuphine to see if Anrikefon can offer effective and safer perioperative analgesia for ophthalmic day-surgery patients. Participants will: * Receive either an intravenous dose of Anrikefon or nalbuphine during surgery. * Be monitored for pain scores, side effects, and recovery parameters after surgery. * Complete follow-up assessments.
Eligibility
Inclusion Criteria5
- Scheduled for ophthalmic surgery under general anesthesia.
- Aged 18 to 70 years.
- With American Society of Anesthesiologists (ASA) physical status I to III.
- Body mass index (BMI) between 18 and 30 kg/m²
- Agree to participate in the trial and provide written informed consent.
Exclusion Criteria9
- History of cardiovascular or cerebrovascular events within the past 6 months, including unstable angina, ischemic myocardial infarction, or heart failure; or current presence of uncontrolled hypertension (\>180/110 mmHg), aneurysm, or severe cardiac arrhythmia.
- Severe respiratory diseases such as pulmonary fibrosis, severe pulmonary abscess, cor pulmonale, or advanced chronic obstructive pulmonary disease (COPD).
- Significant neurological disorders such as brain injury or seizures, as well as severe psychiatric illnesses.
- Known allergy to kappa opioid receptor agonists or to general anesthetic agents used in this study.
- Current peptic ulcer disease, gastrointestinal bleeding, or known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs), such as flurbiprofen axetil or paracetamol.
- Prior use of opioid or non-opioid analgesics, with the last administration occurring within five half-life periods of the drug.
- Continuous use of opioid analgesics for more than 10 days within the 3 months prior to screening.
- Use of drugs with unknown half-life periods that may affect analgesic efficacy within 14 days before randomization.
- History of major surgery within the past 3 months that may interfere with postoperative pain assessment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Anrikefon is a novel peripherally KOR agonist independently developed in China. In this study, anrikefon will be administered intravenously at a dose of 1 μg/kg, 15 minutes before the end of surgery.
Nalbuphine is a traditional central KOR agonist with mixed μ-opioid receptor antagonist activity. In this study, nalbuphine will be administered intravenously at a dose of 0.1 mg/kg, 15 minutes before the end of surgery.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07269106